Hepatitis B Virus
Conditions
Keywords
HBV, VITAMIN D, PEGITERFERON, Telbivudine
Brief summary
Abstract Telbivudine is a potent inhibitor of HBV but, due to a low genetic barrier to resistance, a high incidence of resistance has been observed in patients with high baseline levels of replication and in those with detectable HBV DNA after 24 weeks of therapy (A1). Telbivudine might be used in patients with good predictors of response (HBV DNA \<2 X 106 IU/ ml, i.e. approximately 107 copies/ ml, or 6.3 log 10 IU/ ml at baseline) with verification of HBV DNA suppression below detection in real time PCR assay at 24 weeks.(EASL Guidelines for HBV 2009) The therapy of Pegylated-interferon-alpha-2a is considered as the standard of care for patients with chronic hepatitis b viral infection. However, recent study by Buster et al showed that a sustained viral response (SVR less than 2000 iu.ml at 6 months after treatment)) is obtained in 8 % of patients with genotype D, 30% genotype A, and 20-25% genotypes B or C (47). Vitamin D is a potent immune-modulator; and has been shown to improve SVR in combination with peg interferone in patients with chronic HCV viral infection (48). The impact of vitamin D on virologic response rates of interferon-based treatment of CHB is unknown. The aim of this study therefore was to assess whether Vitamin D, added to the conventional peg therapy in CHB, or to nucleotide analogues could improve the treatment efficacy
Interventions
DRUGPeginterferon + Vitamin D
180 mcg/week + 400 IUX2/day
DRUGPeginterferon
180 mcg/week
DRUGSebivo
Telbivudine 600 mg daily
DRUGentecavir+ vitamin d
entecavir 1 mg daily+ vitamin d
Sponsors
Ziv Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients were eligible if they had been HBsAg positive for at least 6 months, * patients were HBeAg positive or negative, * patients had increased serum ALT levels between 1 and 10 times the upper limit of normal (ULN), * patients had serum HBV-DNA levels greater than 1.0 x 10E5 copies/mL (2.0 X 10E4 IUmL), and * patients had findings on a liver biopsy within the preceding 12 months that were consistent with the presence of chronic hepatitis B.
Exclusion criteria
* decompensated liver disease, * antiviral therapy within 6 months before randomization, * viral co-infections (hepatitis C virus, hepatitis delta virus, or human immunodeficiency virus), or * pre-existent neutropenia or thrombocytopenia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| treatment efficacy | 120 weeks | The primary end point will be sustained viral response which was defined as clearance of HBeAg from serum and HBV DNA less than 10,000 copies/mL (2000 IU/mL) at 6 months after treatment. HBsAg titre during treatment and at 6 months follow up will be measured also (ROCH or Abott Kit). |
| histologic response | 120 WEEKS | Another primary endpoint will be histologic response (reduction of at least two points without fibrosis worsening in the total score on the Histological Activity Index). |
Countries
Israel
Contacts
Primary ContactAssy Nimer, MD
Outcome results
None listed